Clinical Trial Update: Safety and Efficacy of Vildagliptin Versus NPH Insulin add-on to Glimepiride in Type 2 Diabetes Mellitus Patients. [Phase 4]

View source ↗

Summary

Phase 4 trial evaluating safety and efficacy of adding vildagliptin versus NPH insulin to glimepiride in adults with Type 2 diabetes mellitus.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• Amaryl (glimepiride) (glimepiride)
• Galvus (vildagliptin) (vildagliptin)
• NPH insulin (insulin isophane)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Type 2 Diabetes Mellitus | Phase 4 | Status: COMPLETED